Results 251 to 260 of about 3,242,059 (273)
Some of the next articles are maybe not open access.
[Evaluation of CA 15-3 radioimmunoassay].
Gan to kagaku ryoho. Cancer & chemotherapy, 1987The CA 15-3 RIA kit (Centocor Co.) based on a solid-phase radioimmunoassay was evaluated both experimentally and clinically. The results of a basic study of the reproducibility, recovery and dilution were very satisfactory. Serum levels of CA 15-3 were determined in 211 patients with malignancies including 13 breast cancers, 81 patients with benign ...
Y, Takemori +9 more
openaire +1 more source
1995
CA 15-3 is a 290 000 Da cell surface antigen defined by a heterologous monoclonal antibody system employing two distinct antibodies. The first antibody — 115D8 — is specific for a human milkfat globule membrane antigen, whilst the second — DF3 — was derived by immunization with a membrane enriched fraction from human breast carcinoma.
openaire +1 more source
CA 15-3 is a 290 000 Da cell surface antigen defined by a heterologous monoclonal antibody system employing two distinct antibodies. The first antibody — 115D8 — is specific for a human milkfat globule membrane antigen, whilst the second — DF3 — was derived by immunization with a membrane enriched fraction from human breast carcinoma.
openaire +1 more source
La Revue de medecine interne, 1995
The precise clinical value of CA 15-3 antigen has yet to be determined. With no role in screening for early breast cancer and, even if CA 15-3 seems to be correlated with bulky initial tumor burden, it appears to have no independent prognostic value. The clinical interest of CA 15-3 remains the early detection of the first recurrence.
E, Antoine, L, Kayitalire, M, Spielmann
openaire +1 more source
The precise clinical value of CA 15-3 antigen has yet to be determined. With no role in screening for early breast cancer and, even if CA 15-3 seems to be correlated with bulky initial tumor burden, it appears to have no independent prognostic value. The clinical interest of CA 15-3 remains the early detection of the first recurrence.
E, Antoine, L, Kayitalire, M, Spielmann
openaire +1 more source
Tumor Marker CA 15-3 in Hematological Malignancies.
Blood, 2006Abstract Introduction: CA 15-3 is a glycoprotein expressed in several adenocarcinomas, especially of the breast. It is used to detect recurrent or metastatic disease. Elevated levels can also be found in adenocarcinomas of the ovary, lung, pancreas, and colon, and are also related to benign breast or ovarian disease, endometriosis ...
Charalambos Andreadis +7 more
openaire +1 more source
La Revue de Médecine Interne, 1994
Resume La place exacte du CA 15-3, en oncosenologie clinique, reste actuellement a definir. D'aucune utilite dans une strategie de depistage et, bein que probablement correle a la masse tumorale initiale, le CA 15-3 apparait egalement depourvu, du moins au stade diagnostique, de toute valeur pronostique independante.
E Antoine, L Kayitalire, M Spielmann
openaire +1 more source
Resume La place exacte du CA 15-3, en oncosenologie clinique, reste actuellement a definir. D'aucune utilite dans une strategie de depistage et, bein que probablement correle a la masse tumorale initiale, le CA 15-3 apparait egalement depourvu, du moins au stade diagnostique, de toute valeur pronostique independante.
E Antoine, L Kayitalire, M Spielmann
openaire +1 more source
Serum levels of the oncofetal antigens CA-125, CA 19-9 and CA 15-3 in patients with endometriosis
Journal of Endocrinological Investigation, 1988The levels of the oncofetal antigens CA-125, CA 19-9 and CA 15-3 were measured in serum samples taken from 8 women, aged 21 to 37 yr, before treatment, during the last fifteen days of a 6-month administration of danazol and finally three months after treatment withdrawal.
D, Panidis +4 more
openaire +2 more sources
Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie, 2017
D. Brüggmann +5 more
openaire +1 more source
D. Brüggmann +5 more
openaire +1 more source